Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-bkjnw Total loading time: 0.505 Render date: 2021-10-18T04:05:14.368Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

12 - Lung cancer staging

from Section IV - Malignant conditions of the lung

Published online by Cambridge University Press:  05 September 2016

Bilal H. Kirmani
Affiliation:
Papworth Hospital, Cambridge, UK
Aman S. Coonar
Affiliation:
Papworth Hospital, Cambridge, UK
Marco Scarci
Affiliation:
University College London Hospital
Aman Coonar
Affiliation:
Papworth Hospital
Tom Routledge
Affiliation:
Guy’s Hospital
Get access

Summary

Lung cancer is the second most common cancer in the UK and a leading cause of cancer-related deaths worldwide. Prognosis and treatment options vary depending on the pathological type and the anatomical extent of the tumour. Both over-treatment of advanced disease and under-treatment of limited disease can reduce quality and length of life. Therefore, prompt and accurate staging are important to ensure delivery of appropriate therapy.

Clinical presentation

A large proportion of primary lung cancers are asymptomatic, and poor awareness of signs and symptoms of lung cancer in the general population means that patients often present late. Clinical features identified by careful history and examination can direct tests. More recently, the increasing availability of CT screening has led to an increased detection of early cancers, and this may result in a real survival advantage by curing disease found at an early stage. Alternatively, it may just represent a lead-time bias.

Staging systems

Staging helps in advising on prognosis, planning treatment and comparing data. There are two parts, the TNM (tumour, node, metastasis) and the stage groups.

Different TNM combinations have been aggregated into stage groups that differ by their prognosis. The TNM and stage groups are based on the outcomes of many pragmatically managed patients and undergo periodic review. This means there can be differences between versions, and while these may be small, users should be aware of them.

TNM status

The TNM status describes the anatomical extent of cancer based on tumour size, location and any local invasion, lymph node involvement and metastasis. Nodal involvement is described based on lymph node stations, as described by Mountain and Dresler.

The seventh and most recent revision of the TNM staging system for lung cancer, summarized in Table 12.1, started to be used in 2010. It is based on multicentre data from more than 80,000 patients. At various stages of the diagnostic pathway, the patient's TNM status can be updated. The clinical stage (cTNM) and the pathological stage (pTNM) (post-operative) have different prognoses. It is important to note that the data set employed to determine the seventh edition of the TNM classification predated the widespread use of positron-emission tomography (PET) scanning and therefore does not fully reflect the importance of that tool, which is now a standard of care for lung cancer staging in the UK and many other places.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Rostad, H, Vale, JR, Nesthus, I. Lung cancer: symptoms, signs and diagnostic criteria. Scand J Respir Dis 1979;60:184–90.Google Scholar
2 Simon, AE, Juszczyk, D, Smyth, N, et al. Knowledge of lung cancer symptoms and risk factors in the UK: development of a measure and results from a population-based survey. Thorax 2012; 67:426–32. doi:10.1136/thoraxjnl-2011-200898.CrossRefGoogle Scholar
3 International Early Lung Cancer Action Program Investigators, Henschke, CI, Yankelevitz, DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355:1763–71. doi:10.1056/NEJMoa060476.CrossRefGoogle Scholar
4 Mountain, CF, Dresler, CM. Regional lymph node classification for lung cancer staging. Chest J 1997; 111:1718–23. doi:10.1378/chest.111.6.1718.CrossRefGoogle Scholar
5 Goldstraw, P, Crowley, J, Chansky, K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2007; 2:706–14. doi:10.1097/JTO.0b013e31812f3c1a.CrossRefGoogle Scholar
6 Kirmani, BH, Rintoul, RC, Win, T, et al. Stage migration: results of lymph node dissection in the era of modern imaging and invasive staging for lung cancer. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg 2013; 43:104–9; discussion 109–110. doi:10.1093/ejcts/ezs184.CrossRefGoogle Scholar
7 Robinson, LA, Ruckdeschel, JC, Wagner, H, et al. Treatment of Non-small Cell Lung Cancer-Stage IIIA. Chest 2007;132:243S–65S. doi:10.1378/chest.07–1379.CrossRefGoogle Scholar
8 Sastry, P, Tocock, A, Coonar, AS. Adrenalectomy for isolated metastasis from operable non-small-cell lung cancer. Interact Cardiovasc Thorac Surg 2014; 18:495–7. doi:10.1093/icvts/ivt526.CrossRefGoogle Scholar
9 Coory, M, Gkolia, P, Yang, IA, et al. Systematic review of multidisciplinary teams in the management of lung cancer. Lung Cancer 2008; 60:14–21. doi:10.1016/j.lungcan.2008.01.008.CrossRefGoogle Scholar
10 Yasufuku, K, Nakajima, T, Motoori, K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006; 130:710–18. doi:10.1378/chest.130.3.710.CrossRefGoogle Scholar
11 Yi, CA, Shin, KM, Lee, KS, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 2008; 248:632–42. doi:10.1148/radiol.2482071822.CrossRefGoogle Scholar
12 Quint, LE. Staging non-small cell lung cancer. Cancer Imaging 2007; 7:148–59. doi:10.1102/1470–7330.2007.0026.CrossRefGoogle Scholar
13 Marom, EM, McAdams, HP, Erasmus, JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803–9. doi:10.1148/radiology.212.3.r99se21803.CrossRefGoogle Scholar
14 He, Y-Q, Gong, H-L, Deng, Y-F, et al. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol Stockh Swed 1987 Published online first: 30 September 2013. doi:10.1177/0284185113498536.CrossRef
15 Fischer, B, Lassen, U, Mortensen, J, et al. Preoperative staging of lung cancer with combined PET–CT. N Engl J Med 2009; 361:32–9. doi:10.1056/NEJMoa0900043.CrossRefGoogle Scholar
16 Coonar, AS, Hughes, JA, Walker, S, et al. Implementation of real-time ultrasound in a thoracic surgery practice. Ann Thorac Surg 2009; 87:1577–81. doi:10.1016/j.athoracsur.2008.12.024.CrossRefGoogle Scholar
17 Sharples, LD, Jackson, C, Wheaton, E, et al. Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomised controlled trial. Health Technol Assess Winch Engl 2012; 16:1–75, iii–iv. doi:10.3310/hta16180.CrossRefGoogle Scholar
18 Leyn, PD, Lerut, T. Conventional mediastinoscopy. Multimed Man Cardio-Thorac Surg 2005; doi:10.1510/mmcts.2004.000158.CrossRef
19 Hunt, I, Alwahab, Y, Treasure, T. Using video-assisted thorascoscopy (VATS) to aid the anterior mediastinotomy approach to mediastinal masses. Ann R Coll Surg Engl 2007; 89:435–6. doi:10.1308/003588407X183517d.CrossRefGoogle Scholar
20 Meerbeeck, JP, Kramer, GWPM, Schil, PEYV, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in Stage IIIA-N2 non–small-cell lung cancer. J Natl Cancer Inst 2007; 99:442–50. doi:10.1093/jnci/djk093.CrossRefGoogle Scholar
21 DeCamp, MM, Ashiku, S, Thurer, R. The role of surgery in N2 non-small cell lung cancer. Clin Cancer Res 2005;11:5033s–7s. doi:10.1158/1078-0432.CCR-05–9013.CrossRefGoogle Scholar
22 Goldstraw, P, Mannam, GC, Kaplan, DK, et al. Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 1994; 107:19–28. doi:.Google Scholar
23 Andre, F, Grunenwald, D, Pignon, JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol Off J Am Soc Clin Oncol 2000; 18:2981–9.Google Scholar

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×